LON:BVX BiVictriX Therapeutics (BVX) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BiVictriX Therapeutics Stock (LON:BVX) 30 days 90 days 365 days Advanced Chart Remove Ads Get BiVictriX Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range 10▼ 1052-Week Range N/AVolume1.54 million shsAverage Volume108,326 shsMarket Capitalization£8.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.Read More… Remove Ads Receive BVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiVictriX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BVX Stock News HeadlinesBivictrix quits London’s AIM to chase private funding as market ‘undervalues’ firmAugust 12, 2024 | msn.comBiVictriX Therapeutics Proposes Delisting From London's AIMAugust 12, 2024 | marketwatch.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 1, 2025 | American Alternative (Ad)BiVictriX Therapeutics PLC (BVX)April 17, 2024 | investing.comWhen Will BiVictriX Therapeutics Plc (LON:BVX) Turn A Profit?February 15, 2024 | finance.yahoo.comBiVictriX Therapeutics' former chair moves onDecember 6, 2023 | proactiveinvestors.comBRIEF-Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid LeukaemiaOctober 12, 2023 | reuters.comBiVictriX says latest preclincial leukaemia data could accelerate progressOctober 12, 2023 | proactiveinvestors.comSee More Headlines BVX Stock Analysis - Frequently Asked Questions How do I buy shares of BiVictriX Therapeutics? Shares of BVX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of BiVictriX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that BiVictriX Therapeutics investors own include AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX), Abacus Health Products (ABAHF) and Aurora Cannabis (ACB). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:BVX CIKN/A Webwww.bivictrix.com PhoneN/AFaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-103.99% Return on Assets-62.99% Debt Debt-to-Equity Ratio8.81 Current Ratio4.40 Quick Ratio7.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow2.20 Book ValueGBX 3 per share Price / BookN/AMiscellaneous Outstanding Shares82,530,000Free FloatN/AMarket Cap£8.25 million OptionableNot Optionable Beta-0.73 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (LON:BVX) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiVictriX Therapeutics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share BiVictriX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
